Journal of Psoriasis and Psoriatic Arthritis最新文献

{"title":"Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis.","authors":"Malak Al-Gawahiri, Elke M G J de Jong, Ellen J H Schatorjé, Esther P A H Hoppenreijs, Juul M P A van den Reek, Marieke M B Seyger","doi":"10.1177/24755303261446205","DOIUrl":"10.1177/24755303261446205","url":null,"abstract":"<p><strong>Background: </strong>Early identification and treatment of psoriatic arthritis (PsA) among patients with psoriasis is important to prevent joint damage. Insights in arthritis onset and the associated clinical factors among pediatric and young adult patients with psoriasis is scarce.</p><p><strong>Objectives: </strong>To describe pediatric patients with psoriasis who subsequently developed psoriatic arthritis at pediatric age or in young adulthood (JPsA/PsA). We focused on clinical features and timing of onset, and compared clinical features to characteristics of a large cohort of pediatric psoriasis patients.</p><p><strong>Methods: </strong>Data on patients with pediatric onset of psoriasis were obtained from the prospective, daily practice, ChildCAPTURE registry. Descriptive statistics were used. ILAR and CASPAR criteria were used for classification of JPsA and PsA, respectively. The time to JPsA/PsA diagnosis following psoriasis onset was analyzed using Kaplan-Meier survival analysis.</p><p><strong>Results: </strong>Among 717 pediatric and young adult patients with psoriasis, 15 (2.1%) developed arthritis, of which 8 patients before the age of 18 years (1.1%, JPsA) and 7 patients in young adulthood (1.0%, PsA), with an estimated incidence of 2.8% within 10 years after psoriasis diagnosis. The median interval between psoriasis onset and JPsA/PsA development was 4.8 years. Male sex, obesity, and nail involvement were common clinical features of patients developing JPsA/PsA, and these were observed more frequently compared to the total pediatric psoriasis cohort.</p><p><strong>Conclusion: </strong>The incidence of JPsA/PsA among patients with pediatric onset of psoriasis is low. If the clinical features male sex, obesity and nail involvement are present, extra awareness for the development of JPsA/PsA is warranted.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446205"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Enthesitis in Psoriasis Patients as Predictors of Arthritis: The EPESCA Study.","authors":"Eleonora Di Donato, Andrea Becciolini, Sergio Di Nuzzo, Nataliya Chernyschova, Claudio Commisso, Sveva Lamorte, Carolina Fantini, Francesca Satolli, Daniele Santilli, Gianluca Lucchini, Claudio Feliciani, Nicola Sverzellati, Alarico Ariani","doi":"10.1177/24755303261446216","DOIUrl":"10.1177/24755303261446216","url":null,"abstract":"<p><p><b>Background:</b> Enthesitis, a key feature of psoriatic arthritis (PsA), can be detected subclinically by ultrasound (US) in patients with psoriasis (PsO), where it may signal an increased risk of future articular involvement. <b>Purpose:</b> This observational study aimed to investigate the prevalence of subclinical enthesitis in PsO patients without musculoskeletal symptoms, analyze the differences between patients with enthesis alterations (i.e. active enthesitis - AE, inactive enthesitis - En, enthesopathy - Ep or none - wE, per OMERACT criteria) and evaluate the 1 year PsA incidence. <b>Research design:</b> All consecutive PsO patients ≥18 years attending a dermatology outpatient clinic were screened. A rheumatologist and a radiologist experienced in US performed greyscale and Power Doppler (PD) examination on six bilateral enthesal sites (Achilles, quadriceps, distal/proximal patellar, plantar fascia, and triceps enthesis). The chi-square test or Kruskall-Wallis test detected the differences between the groups. After 1 year, rheumatologists reassessed En and AE patients for PsA onset. A <i>P</i>-value ≤0.05 was considered statistically significant. <b>Results:</b> Among 211 enrolled subjects, AE, En, and Ep prevalences were 6.6%, 35.6%, and 31.8%, respectively. There were no alterations in 23.2% while 2.8% showed only PD signal. BMI was higher in En than in wE and Ep (28, 24 and 25 kg/m^2 respectively) (<i>P</i> < 0.05). Female were less prevalent in En than in Ep (52% vs 25%, <i>P</i> < 0.01). None developed PsA during the 1-year follow-up. <b>Conclusion:</b> Subclinical enthesitis is common in PsO patients (about 40%), with inactive enthesitis more frequent in higher-BMI individuals. Active enthesitis was rare (<7%), and no cases progressed to PsA.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446216"},"PeriodicalIF":0.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13095994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter From the New Editor-in-Chief.","authors":"George Han","doi":"10.1177/24755303261432372","DOIUrl":"10.1177/24755303261432372","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261432372"},"PeriodicalIF":0.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12971499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registry.","authors":"Miranda K Chen, Petronilla Biwott, Isabel Muraguri, Georgia Marquez-Grap, Gian Carlo Baldonado, Payton Smith, Toby Maurer, Tina Bhutani, Samson Kiprono, Wilson Liao","doi":"10.1177/24755303261433913","DOIUrl":"10.1177/24755303261433913","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis is a chronic immune-mediated disease with global prevalence of 2-3% that is associated with significantly reduced quality of life (QoL) and worsened mental health. Despite this, there is a lack of research in African psoriasis populations, with no modern epidemiological studies conducted in Kenya to examine these factors. This study aims to identify demographic and clinical features associated with dermatology-related QoL and mental health among psoriasis patients enrolled in the newly established Kenyan Psoriasis Registry (KPR), based at Moi Teaching and Referral Hospital in Eldoret, Kenya.</p><p><strong>Patients and methods: </strong>In a cross-sectional analysis of 97 adult psoriasis patients enrolled in the KPR, we evaluated associations of demographic and disease characteristics with independent outcomes of dermatology-associated QoL (Dermatology Life Quality Index, DLQI), anxiety (Generalized Anxiety Disorder 7-item, GAD-7), and depression (Patient Health Questionnaire 9-item, PHQ-9). Univariate and multivariate linear regression models were used to identify associations, with <i>P</i> < 0.05 considered statistically significant.</p><p><strong>Results: </strong>In univariate analyses, age, female gender, marital status, certain subethnicities, high-impact body sites, itch and pain, sleep disturbance, and disease severity were factors associated with worse QoL, anxiety, and depression scores. In multivariate analyses, younger age, Itch Numeric Rating Scale, and Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance T-score remained significantly associated with worse DLQI. Both PROMIS Sleep Disturbance and separated marital status were associated with worse GAD-7 and PHQ-9.</p><p><strong>Conclusion: </strong>Kenyan psoriasis patients experience significant QoL and mental health burden, with younger age, itch, sleep disturbance, and separated marital status associated with worse outcomes.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261433913"},"PeriodicalIF":0.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12971513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in Bimekizumab Treated Psoriasis Patients With Prior IL-17 Inhibitor Failure.","authors":"Eingun James Song, Prieuer Pretorius, Diego Ruiz Dasilva, Christopher G Bunick, Clive Liu, Mona Shahriari","doi":"10.1177/24755303251412379","DOIUrl":"10.1177/24755303251412379","url":null,"abstract":"<p><p>Despite advancements in psoriasis therapeutics, biologic discontinuation and switching still happen frequently, with the most common reasons being lack of efficacy or treatment intolerance. Conventional teaching has been to switch out of the class (inter-class switching) for primary non-responders and to stay in the class (intra-class switching) for secondary non-responders. Previous real-world studies have reported success with intra-class switching within the IL-17 inhibitor class, but data have been limited to secukinumab, ixekizumab, and brodalumab. Using retrospective data from cases selected for moderate-to-severe psoriasis who failed prior IL-17 therapy, we report our real-world experience using bimekizumab in 50 patients who failed a prior IL-17 inhibitor, in which 82% achieved an IGA 0/1. By demonstrating achievement of stringent benchmarks, such as IGA 0/1 and sPGAxBSA 100 in these selected patients, we challenge the conventional teaching of primary vs secondary non-responders class switching, and have found bimekizumab to be a viable option in those who have failed IL-17 inhibitor therapy in the past.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251412379"},"PeriodicalIF":0.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriatic Arthritis Characteristics and Comorbidities in North Africa: Results of a Multicenter Retrospective Study.","authors":"Abderrahim Majjad, Sofia El Guarti, Hamza Mansouri, Tarik Youssoufi, Hasna Hassikou, Krystel Efemba, Taoufik Harzy, Safaa Fellous, Fadwa Allali, Soukaina Kabbou, Imad Ghozlani, Abdellah El Maghraoui, Lahcen Achemlal","doi":"10.1177/24755303251412380","DOIUrl":"10.1177/24755303251412380","url":null,"abstract":"<p><strong>Background: </strong>Psoriatic arthritis (PsA) exhibits heterogeneity across different populations. Given the limited research on PsA in Africa, this study aims to characterize disease features and various cardiovascular disease risk factors (CVRFs) in a cohort of patients with PsA.</p><p><strong>Methods: </strong>We enrolled 110 patients fulfilling the CASPAR criteria. PsA. PsA-related parameters and various CVRFs were recorded. Radiographs of hands and feet assessed peripheral joint damages.</p><p><strong>Results: </strong>The study population included 48 males and 62 females, with a mean age of 49.8 ± 12.5 years and a mean disease duration of 9 ± 7 years. The most common disease pattern was polyarthritis, followed by oligoarthritis, spondyloarthritis, and enthesitis. Dactylitis was reported in 33.9% of patients, while 7.6% carried the HLA-B27 gene. Psoriasis was observed in 74.5% of patients, with nail involvement in 30% of cases. Inflammatory bowel disease and uveitis were present in 4.5% and 1.8% of patients, respectively. 77% of patients had active disease. Radiographic joint damage was detected in 47.2% of patients and was significantly associated with disease duration, dactylitis, and biologic therapy use. In this cohort, 23.6% were obese, and 30% were smokers. Comorbidities such as diabetes, hypertension, hyperlipidemia, and gout were present in 22.7%, 19.1%, 29.1%, and 8.1%, respectively. Moreover, 57.3% of patients had two or more CVRFs and 9.1% had a cardiovascular disease.</p><p><strong>Conclusion: </strong>This cohort suggested a female predominance, a lower prevalence of the HLA-B27 gene, a reduced frequency of extra-musculoskeletal manifestations, and a high prevalence of radiographic joint damage and CVRFs.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251412380"},"PeriodicalIF":0.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12742996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Study.","authors":"Mark Lebwohl, Hideki Fujita, Kilian Eyerich, Andrew E Pink, Min Zheng, Iris Chen-Yin Lai, David Trigos, Anne M Skalicky, Julia R Correll, Ana C Hernandez Daly, Tadashi Terui","doi":"10.1177/24755303251401112","DOIUrl":"10.1177/24755303251401112","url":null,"abstract":"<p><strong>Background: </strong>Generalized pustular psoriasis (GPP) is a rare, serious, chronic, neutrophilic skin disease, distinct from plaque psoriasis, characterized by recurrent flares of cutaneous erythema and widespread sterile pustules. Patient-centric data on the quality of life (QoL) impacts of GPP remain limited.</p><p><strong>Objective: </strong>To evaluate the physical and emotional QoL impacts of GPP.</p><p><strong>Methods: </strong>We used a web-based survey and 90-minute telephone interviews with open-ended questions to evaluate the experiences of adults with GPP across China, Japan, the UK, and the USA. Quantitative measures included the Dermatology Life Quality Index (DLQI), Psoriasis Symptom Scale (PSS), and Worst GPP Pain Numeric Rating Scale (NRS).</p><p><strong>Results: </strong>21 participants completed the survey; 9 completed telephone interviews. The journey to diagnosis was complicated, with 48% of participants seeing ≥4 physicians before the diagnosis. Impacts of GPP on participants physical and mental QoL were substantial, such as the anxiety of not being able to plan life and work with confidence, both in general and during flares. The mean DLQI was 10.2, and the PSS and Worst GPP Pain NRS were highest in participants experiencing recent flares. Participants' biggest worries included risk of flares, distress from symptoms, inadequate treatment, and passing on the disease to their children. Limitations included a small sample size and short recall timeframe.</p><p><strong>Conclusion: </strong>Participants reported multiple impacts of GPP on their daily lives even in the absence of acute flares, highlighting the need for greater disease awareness and understanding among healthcare professionals.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251401112"},"PeriodicalIF":0.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12657205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Contributing Factors for Difficult to Treat Psoriatic Arthritis- a Comparative Analysis.","authors":"Ong Ping Seung, Lee Pei Jia","doi":"10.1177/24755303251394308","DOIUrl":"10.1177/24755303251394308","url":null,"abstract":"<p><strong>Objective: </strong>To assess the contributing factors and clinical characteristics of difficult-to-treat (D2T) psoriatic arthritis (PsA).</p><p><strong>Patients and methods: </strong>This retrospective cross-sectional study included PsA patients from a tertiary care center. D2T PsA was defined as failure of at least 1 conventional synthetic DMARD (csDMARD) and 2 or more biologic/targeted synthetic DMARDs (b/tsDMARDs) with different mechanisms of action. Baseline demographics, disease duration, and domain involvement were compared across groups.</p><p><strong>Results: </strong>A total of 150 PsA patients were included, with an equal gender distribution and a mean age of 55.9 ± 13.7 years. Patients with D2T PsA had a significantly younger age of onset for both psoriasis and PsA (both <i>P</i> < 0.001), and a higher prevalence of obesity (<i>P</i> = 0.018). Multidomain involvement was prominent, with 93.5% of D2T patients having 3 or more domains affected (<i>P</i> < 0.001). Axial disease, dactylitis, enthesitis, and nail involvement were all significantly more frequent in the D2T group (all <i>P</i> < 0.001). Multivariate analysis identified age, age of psoriasis onset, axial involvement, enthesitis, and nail dystrophy as independent predictors of D2T PsA.</p><p><strong>Conclusion: </strong>D2T PsA is associated with early disease onset, obesity, and extensive multi-domain involvement, particularly axial disease, enthesitis, and nail changes. These findings suggest that specific clinical features and comorbidities may help identify patients at risk of developing D2T PsA. Early recognition of these factors may guide more personalized and aggressive treatment strategies to improve long-term outcomes.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251394308"},"PeriodicalIF":0.0,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world Evidence of Brodalumab Safety for the Treatment of Psoriasis.","authors":"Mark Lebwohl, Eingun James Song, Tina Bhutani, Lawrence Green, Abby Jacobson","doi":"10.1177/24755303251382878","DOIUrl":"10.1177/24755303251382878","url":null,"abstract":"<p><p>Plaque psoriasis is a chronic skin disorder involving dysregulated inflammation. While numerous biologic therapies targeting inflammatory mediators have been approved for moderate-to-severe psoriasis, their safety profiles may include an increased risk of adverse events (AEs), such as infections, cardiovascular diseases, and malignancies. Because patients with psoriasis also have increased incidence of comorbidities, long-term real-world AE monitoring is critical to further evaluate the safety of biologic therapies postapproval. Brodalumab is a recombinant, fully human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. The safety profile of brodalumab has been established in clinical trials and industry-sponsored US pharmacovigilance reports. Herein, we summarize AEs reported in nonsponsored open-label and real-world studies of brodalumab. Across all studies, most common AEs were similar to those listed in the brodalumab package insert. While AEs of special interest were not reported comprehensively, their rates were generally low, with 3 cases of major adverse cardiac events, 2 cases of malignancy, 11 cases of depression, and no completed suicides in the overall safety population (N = 1701). There were 6 cases of serious infection and no serious fungal infections. Studies evaluating AEs of interest for brodalumab showed no causal link to suicide and no increase in risk of cardiac events or serious infection compared with other biologics. Together, these studies support a consistent safety profile of brodalumab in real-world use.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251382878"},"PeriodicalIF":0.0,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12552225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Considerations for the Use of Biologic Agents in Psoriasis Patients With a History of Lymphoma.","authors":"Allison Bai, Emily Gartrell, Olivia Whittaker, Jeffrey Sobell","doi":"10.1177/24755303251387119","DOIUrl":"10.1177/24755303251387119","url":null,"abstract":"<p><p><b>Background:</b> Managing psoriasis in patients with a history of lymphoma presents a unique clinical challenge. Psoriasis is associated with significant comorbidities such as cardiovascular disease and inflammatory arthritis, making optimal treatment vital. Systemic treatments like biologic agents may help mitigate these sequelae of systemic inflammation. However, concerns about immunosuppression in the context of lymphoma recurrence and progression complicate therapeutic decisions. <b>Purpose:</b> This review aims to examine the role of IL-12, IL-17, IL-23, and TNF-α in psoriasis and explores the safety of biologic therapies in this population, with a focus on impact on lymphoma recurrence and progression. <b>Research Design:</b> A narrative review of the current medical literature was conducted. <b>Study Sample:</b> The analysis synthesizes evidence from preclinical studies, clinical trials, post-marketing surveillance registries, retrospetive cohort studies, and case reports concerning the use of biologic agents in psoriasis. <b>Data Collection:</b> Relevant literature was identified an analyzed to compare the mechanisms of action, degree of immunosuppression, and available safety data of different biologic agent classes. <b>Results:</b> Based on current evidence, we propose that IL-17 and IL-23 inhibitors as preferred options due to their targeted mechanisms and favorable safety profiles. In contrast, TNF-α inhibitors are less favored due to their comparatively greater immunosuppressive effects and potential association with lymphoma risk. IL-12/23 inhibitors are questionable given their potential impact on tumor immunosurveillance. <b>Conclusion:</b> For psoriasis patients with a history of lymphoma, IL-17 and IL-23 inhibitors represent the most suitable biologic options, while TNF-α inhibitors and IL-12/23 inhibitors should be used with caution. Clinical data overall remains limited, however, as lymphoma patients are routinely excluded from clinical trials. Further research is needed to clarify long-term safety and optimize treatment strategies for this high-risk population.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387119"},"PeriodicalIF":0.0,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12549605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}